Published in Clin Cancer Res on March 15, 2007
Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res (2007) 1.23
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet (2008) 1.14
The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One (2010) 1.02
Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res (2009) 0.96
Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget (2013) 0.94
BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One (2010) 0.88
Dose-dependent activation of putative oncogene SBSN by BORIS. PLoS One (2012) 0.84
Widespread expression of BORIS/CTCFL in normal and cancer cells. PLoS One (2011) 0.83
Increased Intragenic IGF2 Methylation is Associated with Repression of Insulator Activity and Elevated Expression in Serous Ovarian Carcinoma. Front Oncol (2013) 0.83
BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma. Genet Test Mol Biomarkers (2012) 0.82
BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun (2013) 0.81
Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy. Oncotarget (2016) 0.81
BORIS/CTCFL is an RNA-binding protein that associates with polysomes. BMC Cell Biol (2013) 0.79
In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. Int J Mol Sci (2016) 0.78
A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. Exp Mol Med (2016) 0.77
Expression of the CTCFL Gene during Mouse Embryogenesis Causes Growth Retardation, Postnatal Lethality, and Dysregulation of the Transforming Growth Factor β Pathway. Mol Cell Biol (2015) 0.75
Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer. Korean J Thorac Cardiovasc Surg (2014) 0.75
Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells. Sci Rep (2017) 0.75
Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. PLoS One (2017) 0.75
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 6.79
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature (2008) 6.02
CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci U S A (2006) 5.95
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect (2012) 4.89
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol (2004) 4.87
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet (2004) 3.56
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med (2001) 3.22
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
CTCF is conserved from Drosophila to humans and confers enhancer blocking of the Fab-8 insulator. EMBO Rep (2005) 2.80
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
The binding sites for the chromatin insulator protein CTCF map to DNA methylation-free domains genome-wide. Genome Res (2004) 2.78
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr Biol (2004) 2.67
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med (2009) 2.60
Gene expression analysis reveals chemical-specific profiles. Toxicol Sci (2002) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Scientific collaboration results in higher citation rates of published articles. Pharmacotherapy (2006) 2.39
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Three microarray platforms: an analysis of their concordance in profiling gene expression. BMC Genomics (2005) 2.29
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance. Mol Cell Biol (2004) 2.24
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res (2010) 2.13
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08
CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide. Mol Cell Biol (2007) 2.07
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell (2004) 2.05
Does CTCF mediate between nuclear organization and gene expression? Bioessays (2010) 2.02
Universal Reference RNA as a standard for microarray experiments. BMC Genomics (2004) 2.00
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Identification of the single base change causing the callipyge muscle hypertrophy phenotype, the only known example of polar overdominance in mammals. Genome Res (2002) 1.91
Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis (2004) 1.91
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res (2007) 1.91
The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. Hum Mol Genet (2005) 1.88
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res (2006) 1.87
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
Prediction of compound signature using high density gene expression profiling. Toxicol Sci (2002) 1.82
Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis (2003) 1.82
Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem (2002) 1.81
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) (2009) 1.78
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem (2004) 1.76
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74
Chromosome transfer induced aneuploidy results in complex dysregulation of the cellular transcriptome in immortalized and cancer cells. Cancer Res (2004) 1.74
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol (2008) 1.65
Outcomes from leiomyoma therapies: comparison with normal controls. Obstet Gynecol (2010) 1.64
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene (2004) 1.63
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res (2006) 1.61
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. Epigenetics (2011) 1.60
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57